Biomedical Technology

SinoMab BioScience Limited

🌍 Official Website 🏢 HKSTP Source
52 Potential

Decision Maker

Dr. Shawn Leung
shawn@sinomab.com
+852 3426 9833
Units 303 and 305 to 307, Building 15W, No. 15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong
Raw Description
SinoMab Bioscience Limited (SinoMab) is a private company established in 2001 by a team of antibody and biotechnology professionals. It is a clinical stage biopharmaceutical company that creates and develops therapeutic antibodies. | SinoMab has obtained three Investigational New Drug (IND) approval from China FDA for developing one of its lead products for non-Hodgkin’s Lymphoma (NHL) (淋巴癌), systemic lupus erythematosus (SLE) (紅斑狼瘡) and rheumatoid arthritis (RA) (類風濕關節炎). | Therapeutic Monoclonal antibodies including and Sm03 and SM09, and other Biosimilars. | Description | SinoMab Bioscience Limited (SinoMab) is a private company established in 2001 by a team of antibody and biotechnology professionals. It is a clinical stage biopharmaceutical company that creates and develops therapeutic antibodies. SinoMab has obtained three Investigational New Drug (IND) approval from China FDA for developing one of its lead products for non-Hodgkin’s Lymphoma (NHL) (淋巴癌), systemic lupus erythematosus (SLE) (紅斑狼瘡) and rheumatoid arthritis (RA) (類風濕關節炎). || Product | Therapeutic Monoclonal antibodies including and Sm03 and SM09, and other Biosimilars.

Strategic Analysis

Executive Brief

SinoMab BioScience Limited is a clinical-stage biopharmaceutical company specializing in the discovery and development of monoclonal antibodies (mAbs) and biosimilars. Their primary focus is on immunotherapy for chronic inflammatory diseases and oncology (NHL, SLE, and RA). While their core product is biological, their operational success relies heavily on high-sensitivity analytical chemistry, clinical diagnostics, and the management of complex pharmaceutical manufacturing waste streams.

Strategic Fit & Lead Score

Lead Score: 52 (40-59: General Research / Engineering)

Why this Score? SinoMab is not a traditional "diamond consumer" in the electronics or tooling sense. However, as a high-end biopharma firm, they face significant bottlenecks in trace-level analyte detection during drug development and stringent environmental regulations regarding pharmaceutical effluent. 6C's Boron Doped Diamond (BDD) technology offers a paradigm shift for their analytical labs and their manufacturing sustainability (Wastewater Treatment).

6C Solutions Proposal

Application Area 6C Solution Technical Value Prop
Analytical Sensing BDD Electrochemical Electrodes BDD offers the widest potential window of all materials, allowing SinoMab to detect drug metabolites and biomarkers that are "invisible" to gold or carbon electrodes due to water electrolysis.
Manufacturing Waste BDD-based Advanced Oxidation (EAOP) Efficiently mineralize non-biodegradable pharmaceutical active ingredients (APIs) in wastewater. 6C's BDD electrodes generate hydroxyl radicals directly, reducing TOC (Total Organic Carbon) more effectively than chemical treatments.
Bio-Imaging R&D SCD with NV Centers Use 6C's Single Crystal Diamond for quantum sensing. NV (Nitrogen-Vacancy) centers allow for non-invasive, high-sensitivity magnetic and thermal imaging at the cellular level to track antibody-cell interaction.
Process Purity 9N H2 Generators For specialized lab environments requiring ultra-pure hydrogen for chromatography or controlled atmosphere R&D, 6C's proprietary H2 systems ensure zero contamination.

Engagement Hooks

  • Technical Question: "During your HPLC or electrochemical analysis of monoclonal antibody metabolites, are you limited by the narrow potential window of traditional electrodes, or do you experience electrode fouling that compromises your sensitivity in complex bio-matrices?"
  • Value Statement: "6C's Boron Doped Diamond technology can expand your analytical detection limits and provide a maintenance-free solution for the mineralization of toxic pharmaceutical effluents in your manufacturing pipeline."